Crystagen
Also known as: Cristagen, Chrystagen, EDP, Glu-Asp-Pro
2 notable studies · 3 references
TLDR
Crystagen is the synthetic tripeptide Glu-Asp-Pro (EDP), studied primarily within the Khavinson peptide-bioregulator program for immune aging and lymphoid-tissue regulation, but its direct peer-reviewed evidence is extremely limited, its best indexed study reports a mixed B-cell effect with no improvement in spleen cell renewal, and frequently cited human immune benefits derive from low-certainty developer/patent evidence rather than independently replicated clinical trials.
Research Supports
- Studied for effects on immune aging, particularly B-cell activity in aging spleen tissue
- Investigated for thymic aging and immune-cell changes in irradiated-rat models
- Referenced in developer/patent reports on immune-profile measures in older adults
- Discussed in molecular-modeling work proposing chromatin/DNA interactions for this peptide family
Observations Reported in Research
- Activated the B-cell arm of immunity but did not promote cellular renewal in aging spleen tissue (Chervyakova et al., 2014)
- Reported immune-profile normalization in 82% of patients versus 56% with standard treatment alone, per patent/developer-level evidence rather than a peer-reviewed RCT
- Molecular modeling proposed an interaction between EDP and an AGAT DNA sequence, a hypothesis rather than a demonstrated human mechanism
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic tripeptide; short peptide bioregulator; experimental immune-associated peptide
Crystagen is generally identified in the Khavinson literature as the tripeptide Glu-Asp-Pro or EDP. Khavinson It is associated primarily with immune aging, spleen biology, lymphocytes, thymic/immune regulation, and chromatin/gene-regulatory hypotheses. But Crystagen has one of the weakest direct publication records among the bioregulators we've examined. The clearest PubMed-indexed compound-specific primary paper is a 2014 study comparing several peptides in aging spleen tissue. It reported that Crystagen activated the B-cell arm of immunity, while also reporting an important negative result: Crystagen did not promote cellular renewal in the aging spleen in that experiment. There are also human immune-improvement claims frequently quoted online, including the famous 82% vs 56% “immunogram normalization” result. That result is repeated in a 2021 review, but closer examination shows that the underlying evidence traces to the developers' patent/report rather than a transparent peer-reviewed randomized trial. That distinction belongs on Aminodex.
What Is Crystagen?
Crystagen is a very short peptide: Glu-Asp-Pro (EDP). It belongs to the same short-peptide research program as Livagen, Epitalon, Cortagen, Pinealon, Vesugen, and Cartalax. A broader 2016 mechanistic paper explicitly lists Cristagen = EDP and models EDP as interacting with a particular DNA sequence. Khavinson Commercial sources sometimes describe Crystagen as a “thymus peptide,” but Aminodex should be more careful: Crystagen/EDP ≠ Thymalin. Thymalin is a complex thymic peptide preparation. Crystagen is a defined three-amino-acid peptide. Evidence for Thymalin cannot automatically be assigned to Crystagen.
What Are Researchers Studying?
Immune aging
The primary indexed Crystagen study examined several short peptides in relation to aging of the spleen. Crystagen was reported to activate the B-cell component of immune function but, unlike some comparator peptides, did not stimulate cellular-renewal processes in aging spleen tissue. That's a mixed result—and Aminodex should preserve the negative half instead of reducing the paper to “Crystagen rejuvenates immunity.”
B-cell biology
The 2014 study specifically associates Crystagen with activation of B-cell immunity. However, the study doesn't establish that administering Crystagen improves antibody responses, prevents infection or restores immune competence in humans.
T-cell/immune profiles in older adults
A frequently repeated report claims that Crystagen added to standard treatment normalized immune-profile measurements in 82% of older patients versus 56% receiving standard treatment alone, including reported changes in CD3+, CD4+ and CD4+/CD8 measurements. However, the underlying evidence is not a modern peer-reviewed randomized clinical trial. The result traces to patent/developer documentation, with unclear randomization, blinding and methodology. Classify it as human report/patent evidence — very low certainty rather than human clinical trial evidence.
Chromatin and gene regulation
The Khavinson short-peptide model proposes that peptides such as EDP can influence chromatin and gene expression. Molecular modeling work proposed an interaction between EDP and an AGAT DNA sequence. That's hypothesis-generating molecular modeling. It is not equivalent to demonstrating that administered Crystagen enters human immune-cell nuclei, binds that DNA sequence and produces a clinically beneficial transcriptional program.
Thymic aging
A review from the originating group describes experiments in gamma-irradiated rats in which Crystagen was associated with preservation of thymic cortex-medulla organization and changes in macrophages, mast cells and thymocyte proliferation. Because the readily accessible evidence is largely a secondary summary from the same research network, this should be classified below independently replicated primary evidence.
How Does It Work?
Not established. The proposed model is: Crystagen / EDP → cellular uptake → possible nuclear entry → possible chromatin/DNA interaction → changes in immune-cell gene expression → altered immune-cell behavior. The weakest arrow is the important one: molecular docking / sequence interaction hypothesis ≠ demonstrated in-vivo human mechanism. No well-established conventional receptor has been identified for Crystagen.
What Does the Research Show?
Human research
Extremely limited / very low certainty. There are human immune-function claims in the originating group's literature, but the widely repeated 82% vs 56% result does not come from a transparent modern randomized controlled trial. No independently replicated Crystagen RCT or established human pharmacokinetic program was identified. Score: Human evidence VERY LOW rather than none, because human observations/reports do exist.
Animal research
Limited. Aging spleen and thymic-aging/radiation models provide preclinical signals, but the literature is small and overwhelmingly concentrated within one research lineage.
In-vitro research
Limited. Mechanistic research includes immune-tissue/cell work and broader short-peptide chromatin/DNA models. Evidence involving Thymalin should not automatically become Crystagen evidence.
Notable Studies
Molecular Aspects of Immunoprotective Activity of Peptides in Spleen During the Ageing Process
animalResearchers compared Vilon, Thymogen, Crystagen and R-1. Crystagen was reported to activate the B-cell component of immunity, but did not affect cellular-renewal processes in the aging spleen.
Limitations: Small, highly specialized preclinical literature from the originating research network; no demonstration of improved infection resistance or clinical immune outcomes in humans. Source type: Preclinical — aging spleen model (dropdown set to Animal).
View publication →Crystagen immune-profile observations in elderly/senile people
humanCrystagen plus standard treatment was reported to normalize immune-profile measurements in 82% of patients versus 56% with standard treatment alone, with reported changes particularly involving T-cell measures (CD3+, CD4+, CD4+/CD8). Evidence type: Human report / patent-level evidence. Non-peer-reviewed / patent evidence — not a conventional peer-reviewed randomized clinical trial.
Limitations: The underlying report is not a transparent peer-reviewed randomized clinical trial. Key methodological details are inadequate, independent replication is absent, and later secondary descriptions appear to disagree about administration details. Supporting link is an open-access 2021 review (PMC) discussing Crystagen evidence; Kalios Peptides. No specific PMID was given in the source packet for this report.
View publication →What We Still Don't Know
Human pharmacokinetics; oral bioavailability; plasma half-life; tissue distribution; primary molecular target; whether intact EDP reaches lymphoid tissue in humans; whether proposed DNA interactions occur in vivo; whether it meaningfully improves immune function; whether it reduces infections; whether it improves vaccine responses; whether it reverses immunosenescence; whether B-cell changes translate into functional immunity; long-term safety; autoimmune effects; reproductive safety; whether effects replicate outside the originating research network.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Crystagen research with you.
Get the Aminodex Crystagen Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Chervyakova NA, Linkova NS, Chalisova NI, et al. Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process. Adv Gerontol. 2014;27(1):224–228.
- Khavinson VKh, et al. Review of Thymalin/short-peptide immunoregulatory research, including Crystagen/EDP. 2021.
- Khavinson VKh, Linkova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016;162(2):288–292.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.